Immutep Narrows Eftilagimod Alfa Focus to HNSCC and STS After Manufacturing Discrepancies — Immutep Limited

Event summary

Immutep will focus eftilagimod alfa (efti) development on head and neck squamous cell carcinoma (HNSCC) with CPS < 1 and neoadjuvant soft tissue sarcoma (STS) after identifying manufacturing discrepancies in TACTI-004 trial.
Root cause analysis revealed subtle structural differences between 200L and 2,000L scale production of efti, potentially affecting immune activation.
New 200L manufacturing run contracted; next clinical trials targeted for 2H 2027, subject to regulatory and partnering decisions.
Efti maintains Fast Track designation for HNSCC and Orphan Drug status for STS from FDA.

The big picture

Immutep's strategic pivot reflects the high-stakes balance between leveraging existing clinical data and addressing manufacturing variables that may have undermined TACTI-004. The focus on PD-L1-negative HNSCC and STS aligns with FDA designations but requires proving consistency in efti's immune activation profile. Success hinges on resolving scale-up challenges while maintaining partner and regulatory support in a competitive immuno-oncology landscape.

What we're watching

Regulatory Alignment: Whether FDA feedback will support the revised development path for efti in HNSCC and STS.
Manufacturing Consistency: The pace at which Immutep can resolve production-scale discrepancies and secure sufficient GMP batches.
Partnering Strategy: How discussions with Dr. Reddy's and other potential partners will shape trial timelines and funding.